News

In the first quarter of 2025, 29.7 million transactions were made in the Latvian Medicines Verification System (LZVS), which is slightly more than in the corresponding period of 2024.

Representatives of Arvato Customer Group countries met with system developer Arvato Systems GmbH in Vienna, Austria, on 25 and 26 March to plan further improvements in the National Medicines Verification System.

On 30 January 2025, Arvato Systems held a webinar for IT developers to inform them about the planned updates to the LZVS. Updates will be introduced with the release of Core NMVS 6.0.

9 February 2025 will mark the sixth year of the Medicines Verification System across Europe and in Latvia. During these years, the number of checked and decommissioned medicines packages in the Latvian Medicines Verification System has increased by 37% compared to the first year of operation, the proportion of alerts has significantly decreased, and the LZVS end user registration system has been fully sorted.

Medicines verification has already become a routine process in Apotheka pharmacies, and we fully support the idea of doing everything possible to prevent any potential risks to the safety of medicines.

In line with the deployment of EU Hub Release 1.16, which will take effect on 25 January 2025, the European Medicines Verification Organisation is introducing critical changes to the structure of Product Master Data (PMD) and Product Pack Data (PPD). Additional existing fields will now become mandatory and require action to ensure compliance.